Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery

NCT00041691 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: hMN14 (labetuzumab)

Sponsor

Gilead Sciences